India to Ghana: Albendazole Export Trade Route

To import Albendazole formulations into Ghana, the following approvals and registrations are mandatory:

• Product Registration: All pharmaceutical products must be registered with FDA Ghana prior to importation. The registration process involves submitting a comprehensive dossier, typically in the Common Technical Document (CTD) format, which includes detailed information on product quality, safety, and efficacy. The evaluation process encompasses dossier assessment and, if necessary, facility inspections. Timelines for approval can vary; applicants are advised to consult FDA Ghana for specific durations. Product registration fees are applicable; exact amounts should be confirmed with FDA Ghana. (fdaghana.gov.gh)

• Importer Licensing: Entities intending to import pharmaceutical products must be corporate bodies registered with the Registrar-General's Department and licensed by FDA Ghana. This includes wholesale pharmaceutical companies licensed by the Pharmacy Council and registered by FDA Ghana as importers. Retail pharmacies may import reasonable quantities for retail purposes. (brr.gov.gh)

• Shelf-Life Requirements: Imported products must have at least 60% of their shelf-life remaining upon arrival in Ghana. (brr.gov.gh)

• Import Permits: An import permit from FDA Ghana is required for each consignment. These permits are valid for one year, and applications should be processed ahead of time to ensure compliance. (fdaghana.gov.gh)

• GMP Inspection for Indian Manufacturing Facilities: FDA Ghana may conduct Good Manufacturing Practice (GMP) inspections of foreign manufacturing facilities, including those in India, to ensure compliance with international standards. Manufacturers must provide evidence of GMP certification, and facilities may be subject to periodic inspections by FDA Ghana officials.

Indian exporters of Albendazole formulations must adhere to stringent quality and GMP standards to supply the Ghanaian market:

• GMP Certification: Manufacturing facilities must possess valid GMP certifications recognized by FDA Ghana. This includes compliance with WHO-GMP standards and any additional requirements specified by FDA Ghana.

• Approved Facilities: Facilities such as Taj Pharma India Ltd., located in Gujarat, India, have been approved by FDA Ghana for the manufacture of pharmaceutical products. This approval indicates compliance with FDA Ghana's regulatory standards.

• Regulatory Actions: FDA Ghana actively monitors the market to ensure compliance. In a review of 18 pharmaceutical companies, it was found that certain products, including Albendazole 500mg Tablets, were not registered with FDA Ghana. The authority has recommended identifying and halting the production of unregistered medicines and withdrawing unauthorized products from the market. (audit.gov.gh)

In the past 18 months, FDA Ghana has implemented several regulatory changes affecting pharmaceutical imports:

• Control of Excipients: In February 2024, FDA Ghana issued directives requiring that all batches of imported Glycerin and Propylene Glycol raw materials be accompanied by a certificate of analysis testing for Diethylene Glycol (DEG) and Ethylene Glycol (EG). Finished pharmaceutical products containing these excipients must provide documentary proof of control for DEG and EG. In the absence of such proof, products will be tested at the port of entry at the importer's cost. (fdaghana.gov.gh)

• Adoption of Indian Pharmacopoeia Standards: FDA Ghana has recognized the Indian Pharmacopoeia as an approved reference, provided its monographs align with those of other recognized pharmacopoeias such as the British Pharmacopoeia and the United States Pharmacopoeia. This facilitates the acceptance of products manufactured according to Indian standards, streamlining the registration process for Indian exporters.

These developments underscore FDA Ghana's commitment to ensuring the safety and efficacy of pharmaceutical products in the Ghanaian market.

As of 2025, Ghana's Albendazole market is experiencing significant demand, primarily driven by the high prevalence of helminth infections and government-led deworming initiatives. The World Health Organization (WHO) has identified Ghana as a priority country for mass drug administration programs targeting parasitic worm infections. These programs have been instrumental in increasing the consumption of Albendazole formulations.

In 2024, Ghana imported Albendazole formulations valued at approximately $2.2 million USD from India, accounting for 3.0% of India's total Albendazole formulation exports. This substantial import volume indicates a strong reliance on international suppliers to meet domestic demand. While there is some local pharmaceutical manufacturing capacity, it is limited, and domestic production does not fully satisfy the national requirements for Albendazole formulations.

Ghana applies a zero percent import duty on pharmaceutical products under HS code 30049099, which includes Albendazole formulations. This exemption aligns with the country's commitment to ensuring the availability of essential medicines. Additionally, Ghana imposes a Value Added Tax (VAT) on imports; however, essential medicines are typically exempt from VAT to promote public health objectives. There are no specific Free Trade Agreements (FTAs) between Ghana and India that affect pharmaceutical tariffs, nor are there any anti-dumping duties imposed on Albendazole formulations imported from India.

India is the predominant supplier of Albendazole formulations to Ghana, with exports totaling $2.2 million USD in 2024. Other countries also export Albendazole formulations to Ghana, but their market shares are comparatively smaller. India's competitive pricing, coupled with the high quality of its pharmaceutical products, positions it favorably against competitors from China and European Union manufacturers. The cost-effectiveness of Indian Albendazole formulations, combined with established trade relationships and compliance with international quality standards, reinforces India's leading role in supplying these essential medicines to Ghana.

India is a global leader in the production of generic pharmaceuticals, accounting for approximately 20% of the global supply by volume as of 2024. This extensive manufacturing capability extends to Albendazole formulations, with numerous Indian facilities producing finished dosage forms such as tablets, capsules, and syrups. The country's cost-effective production processes, driven by economies of scale and a well-established supply chain, enable competitive pricing for these formulations. Additionally, India boasts a significant number of WHO-GMP and US FDA-approved manufacturing facilities, ensuring adherence to stringent international quality standards. For instance, Alembic Pharmaceuticals received final US FDA approval for its Albendazole Tablets USP, 200 mg, in September 2024, highlighting the compliance of Indian manufacturers with global regulatory requirements.

When comparing Albendazole formulations from India, China, and the European Union, several factors come into play:

• Price per Unit: Indian manufacturers offer Albendazole formulations at a lower cost compared to their European counterparts, primarily due to lower labor and production costs. Chinese manufacturers also provide competitive pricing; however, concerns about quality have been raised in certain markets.

• Quality Perception: Indian pharmaceutical products are generally perceived as high-quality, especially those from WHO-GMP and US FDA-approved facilities. In contrast, some studies have reported quality issues with Chinese generic drugs, leading to a cautious approach from buyers. European manufacturers are renowned for their stringent quality standards but at a higher price point.

• Regulatory Acceptance in Ghana: Ghana's Food and Drugs Authority (FDA) recognizes and approves pharmaceutical products from WHO-GMP and US FDA-certified facilities, which many Indian manufacturers possess. This facilitates smoother regulatory approval processes for Indian Albendazole formulations in Ghana.

• Supply Reliability: Indian pharmaceutical companies have a strong track record of reliable supply chains, supported by robust manufacturing capacities and established export channels. While Chinese manufacturers have improved their supply reliability, past quality concerns have affected their reputation. European suppliers offer high reliability but may face longer lead times and higher costs.

The India-Ghana supply chain for Albendazole formulations is characterized by:

• Manufacturing Capacity: India's pharmaceutical industry includes numerous large-scale facilities capable of producing substantial quantities of Albendazole formulations. For example, Alembic Pharmaceuticals operates multiple manufacturing units in Gujarat and Sikkim, adhering to international quality standards.

• Packaging and Cold Chain Capabilities: Indian manufacturers are equipped with advanced packaging technologies and, when necessary, cold chain logistics to ensure product stability during transit.

• Regulatory Compliance Track Record: Indian pharmaceutical companies have a strong history of compliance with international regulatory standards, including WHO-GMP and US FDA approvals. This compliance ensures consistent product quality and safety.

• Capacity Constraints or Expansion Plans: To meet growing global demand, Indian manufacturers are continually expanding their capacities. For instance, Sun Pharma announced a significant investment in a new formulations manufacturing facility in Madhya Pradesh in December 2025, aiming to enhance production capabilities.

For Ghanaian buyers sourcing Albendazole formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Albendazole formulations.

• Minimum Order Quantities (MOQs): Be aware that Indian suppliers may have MOQs ranging from 100,000 to 500,000 tablets per order. Negotiating these quantities based on demand forecasts can optimize inventory levels.

• Payment Terms: Standard payment terms in India-Ghana pharmaceutical trade often include a 30% advance payment with the balance payable upon shipment or delivery. Establishing clear payment terms upfront can facilitate smoother transactions.

• Supplier Qualification Process: Conduct thorough due diligence by reviewing potential suppliers' regulatory certifications (e.g., WHO-GMP, US FDA approvals), manufacturing capacities, and quality control measures. Site visits and audits can further ensure compliance with required standards.

• Regulatory Compliance Verification: Ensure that selected suppliers have a history of compliance with international and Ghanaian regulatory requirements to avoid potential importation issues.

By implementing these strategies, Ghanaian buyers can establish a reliable and cost-effective supply chain for Albendazole formulations from India.

By meticulously following these guidelines, Ghanaian companies can establish robust supplier qualification processes, ensuring the procurement of high-quality Albendazole formulations from reputable Indian manufacturers.